Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

benzinga.com/markets/earnings/25/08/46792668/regenerons-pipeline-hit-by-catalent-delays-but-dupixent-shines

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57.
The company reported sales of $3.68 billion, up 4% year over year, beating the consensus of $3.29 billion.
In the…

This story appeared on benzinga.com, 2025-08-01 13:22:46.
The Entire Business World on a Single Page. Free to Use →